Moderna has filed for Emergency Use Authorization (EUA) of its COVID-19 booster vaccine at the 50 µg dose level for all adults ages 18 and older with the U.S. Food and Drug Administration (FDA).
On October 20, the FDA authorized for emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older; people aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2.
The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets.
